News

Filter

Current filters:

Cardio-vascularJapan

1 to 9 of 12 results

Daiichi Sankyo launches new generic drugs

Daiichi Sankyo launches new generic drugs

15-12-2014

Japanese pharma major Daiichi Sankyo says its generics subsidiary, Daiichi Sankyo Espha, has launched…

Antibiotics and Infectious diseasesBlopressCardio-vascularCravitDaiichi SankyoElplatGenericsJapanMarkets & MarketingOncology

MedImmune and Shionogi sign license agreement for Shionogi's preclinical biologics in acute coronary syndrome

MedImmune and Shionogi sign license agreement for Shionogi's preclinical biologics in acute coronary syndrome

09-10-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

BiotechnologyCardio-vascularCrestorJapanLicensingMedImmuneShionogi

Perosphere and Daiichi Sankyo collaborate on Ph III study of PER977 with edoxaban

Perosphere and Daiichi Sankyo collaborate on Ph III study of PER977 with edoxaban

07-10-2014

USA-based Perosphere has entered into a third clinical trial collaboration agreement with Japanese pharma…

Cardio-vascularDaiichi SankyoedoxabanHematologyJapanPER977PerospherePharmaceuticalPortola PharmaceuticalsResearch

Added indication for Daiichi Sankyo’s Lixiana in Japan

Added indication for Daiichi Sankyo’s Lixiana in Japan

29-09-2014

The Japanese Ministry of Health, Labor and Welfare has granted approval for domestic pharma major Daiichi…

Cardio-vascularDaiichi SankyoJapanLixianaPharmaceuticalRegulation

Takeda and BioMotiv in strategic partnership, including investment

Takeda and BioMotiv in strategic partnership, including investment

25-09-2014

Japan’s largest drugmaker Takeda Pharmaceutical has made a strategic investment in USA-based BioMotiv,…

BioMotivCardio-vascularFinancialImmunologicalsInflammatory diseasesJapanPharmaceuticalResearchTakeda PharmaceuticalUSA

Acute coronary syndrome treatment market to more than triple by 2023

Acute coronary syndrome treatment market to more than triple by 2023

30-07-2014

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary…

Acute coronary syndromealirocumabAmgenBayerCardio-vascularEuropeevolocumabJapanMarkets & MarketingMerck & CoPfizerPharmaceuticalSanofiUSAXareltoZontivity

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

10-07-2014

USA-based Portola Pharmaceuticals has entered into a second clinical collaboration agreement with Japanese…

andexanet alfaCardio-vascularDaiichi SankyoedoxabanJapanLicensingPharmaceuticalPortola PharmaceuticalsResearchSavaysaUSA

Third-party investigation confirms Takeda’s systematic involvement in CASE-J Study, but no data tampering

Third-party investigation confirms Takeda’s systematic involvement in CASE-J Study, but no data tampering

23-06-2014

Japan’s largest drugmaker Takeda Pharmaceuticals has updated on the third-party surrounding the results…

BlopressCardio-vascularJapanMarkets & MarketingPharmaceuticalResearchTakeda Pharmaceutical

1 to 9 of 12 results

Back to top